Evolus expands global footprint with debut of Nuceiva in Australia

Evolus has commenced operations in Australia with the launch of Nuceiva or prabotulinumtoxinA. Nuceiva is approved by the Therapeutic Goods Administration TGA for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients . “Launching Evolus in Australia underscores our commitment to strategic geographic expansion and our dedicated focus on customers in this growth market,” said David Moatazedi, President and Chief Executive Officer. “This milestone fuels our global growth strategy by establishing a strong presence in a key region. Successfully entering new markets like Australia positions us for sustained above-market growth, reinforcing Evolus’ position as a global leader in its industry.” Evolus has established a direct operating entity in Australia, under the leadership of Daniel Henry. Working closely with aesthetics healthcare professionals will enable Evolus to offer this new treatment to patients. Nuceiva is licensed in the United States under the brand name Jeuveau and has been the fastest-growing neurotoxin in the United States for three consecutive years.